US20120064021A1 - Dendrobium chysotoxum extract and its cosmetic use as an anti-aging agent - Google Patents
Dendrobium chysotoxum extract and its cosmetic use as an anti-aging agent Download PDFInfo
- Publication number
- US20120064021A1 US20120064021A1 US13/231,466 US201113231466A US2012064021A1 US 20120064021 A1 US20120064021 A1 US 20120064021A1 US 201113231466 A US201113231466 A US 201113231466A US 2012064021 A1 US2012064021 A1 US 2012064021A1
- Authority
- US
- United States
- Prior art keywords
- extract
- skin
- cosmetic composition
- orchid
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000284 extract Substances 0.000 title claims abstract description 108
- 239000002537 cosmetic Substances 0.000 title claims abstract description 43
- 239000003795 chemical substances by application Substances 0.000 title claims description 4
- 241001523681 Dendrobium Species 0.000 title description 5
- 230000003712 anti-aging effect Effects 0.000 title description 5
- 239000000203 mixture Substances 0.000 claims abstract description 67
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 claims abstract description 55
- 230000000694 effects Effects 0.000 claims abstract description 41
- 101710101225 Diablo IAP-binding mitochondrial protein Proteins 0.000 claims abstract description 28
- 101000871228 Homo sapiens Diablo IAP-binding mitochondrial protein Proteins 0.000 claims abstract description 27
- 244000283926 Dendrobium chrysotoxum Species 0.000 claims abstract description 26
- 230000032683 aging Effects 0.000 claims abstract description 22
- 230000014509 gene expression Effects 0.000 claims abstract description 21
- 239000013543 active substance Substances 0.000 claims abstract description 18
- 108010058682 Mitochondrial Proteins Proteins 0.000 claims abstract description 14
- 102000006404 Mitochondrial Proteins Human genes 0.000 claims abstract description 14
- 241000233855 Orchidaceae Species 0.000 claims abstract description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 7
- 230000001737 promoting effect Effects 0.000 claims abstract description 7
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 34
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 15
- 239000002798 polar solvent Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 13
- 241000196324 Embryophyta Species 0.000 claims description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 claims description 8
- 108010002687 Survivin Proteins 0.000 claims description 8
- 102000000763 Survivin Human genes 0.000 claims description 8
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 230000037303 wrinkles Effects 0.000 claims description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 4
- VQLYBLABXAHUDN-UHFFFAOYSA-N bis(4-fluorophenyl)-methyl-(1,2,4-triazol-1-ylmethyl)silane;methyl n-(1h-benzimidazol-2-yl)carbamate Chemical compound C1=CC=C2NC(NC(=O)OC)=NC2=C1.C=1C=C(F)C=CC=1[Si](C=1C=CC(F)=CC=1)(C)CN1C=NC=N1 VQLYBLABXAHUDN-UHFFFAOYSA-N 0.000 claims description 4
- 230000007423 decrease Effects 0.000 claims description 4
- 230000001747 exhibiting effect Effects 0.000 claims description 4
- 239000000419 plant extract Substances 0.000 claims description 4
- 235000021508 Coleus Nutrition 0.000 claims description 3
- 244000061182 Coleus blumei Species 0.000 claims description 3
- 230000036620 skin dryness Effects 0.000 claims description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 2
- 244000124209 Crocus sativus Species 0.000 claims description 2
- 235000015655 Crocus sativus Nutrition 0.000 claims description 2
- 244000163122 Curcuma domestica Species 0.000 claims description 2
- 240000009213 Daniellia oliveri Species 0.000 claims description 2
- 235000005060 Daniellia oliveri Nutrition 0.000 claims description 2
- 241000404336 Lepechinia caulescens Species 0.000 claims description 2
- 240000007225 Limnophila aromatica Species 0.000 claims description 2
- 235000002203 Limnophila aromatica Nutrition 0.000 claims description 2
- 241000195644 Neochloris Species 0.000 claims description 2
- 240000001131 Nostoc commune Species 0.000 claims description 2
- 235000013817 Nostoc commune Nutrition 0.000 claims description 2
- 241000264606 Tetradesmus dimorphus Species 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 235000003373 curcuma longa Nutrition 0.000 claims description 2
- 239000003792 electrolyte Substances 0.000 claims description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 2
- -1 pH adjusters Substances 0.000 claims description 2
- 239000002304 perfume Substances 0.000 claims description 2
- 239000000049 pigment Substances 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 241000565319 Butea monosperma Species 0.000 claims 1
- 241000358848 Orchidantha maxillarioides Species 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 20
- 238000000605 extraction Methods 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- UXDFUVFNIAJEGM-UHFFFAOYSA-N 2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethyl]phenol Chemical compound C1=C(O)C(OC)=CC=C1CCC1=CC(OC)=C(OC)C(OC)=C1 UXDFUVFNIAJEGM-UHFFFAOYSA-N 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 230000006907 apoptotic process Effects 0.000 description 8
- 239000000463 material Substances 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 108010076667 Caspases Proteins 0.000 description 6
- 102000011727 Caspases Human genes 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 210000002510 keratinocyte Anatomy 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000035882 stress Effects 0.000 description 5
- 210000002615 epidermis Anatomy 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 241001313625 Grammatophyllum Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000004042 decolorization Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000012454 non-polar solvent Substances 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 229940043375 1,5-pentanediol Drugs 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- XEFAJZOBODPHBG-UHFFFAOYSA-N 1-phenoxyethanol Chemical compound CC(O)OC1=CC=CC=C1 XEFAJZOBODPHBG-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 108091007065 BIRCs Proteins 0.000 description 1
- 241000726739 Butea Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 101710156605 Diablo homolog, mitochondrial Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 1
- 241000713321 Intracisternal A-particles Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- 230000002225 anti-radical effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000015961 delipidation Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- PKPOVTYZGGYDIJ-UHFFFAOYSA-N dioctyl carbonate Chemical compound CCCCCCCCOC(=O)OCCCCCCCC PKPOVTYZGGYDIJ-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229920006007 hydrogenated polyisobutylene Polymers 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000002803 maceration Methods 0.000 description 1
- 230000037306 mature skin Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 230000037312 oily skin Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8964—Anemarrhena
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9722—Chlorophycota or Chlorophyta [green algae], e.g. Chlorella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/04—Preparations for care of the skin for chemically tanning the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/42—Colour properties
- A61K2800/43—Pigments; Dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
Definitions
- the invention relates to a novel cosmetic composition, comprising at least one extract from the orchid Dendrobium chrysotoxum as an active agent and at least one cosmetically acceptable excipient, in particular for preventing or delaying the appearance of the signs of skin ageing, for slowing or attenuating the effects thereof, or else also for promoting cell or tissue longevity.
- Skin ageing reveals itself in numerous changes intrinsic to the skin and the progressive appearance of visible signs which modify the beauty and the quality of the skin.
- the skin texture is less fine, and numerous skin blemishes develop.
- the ageing results in a progressive deterioration in biological mechanisms such as the slowing of the synthesis of structural proteins (collagen, elastin).
- Apoptosis a type of programmed cell death, is an active biological process of elimination of cells from the body, by fragmentation and under genetic control.
- the elimination can be natural (surplus cells in a tissue) or induced by various stresses.
- the biological cascade of apoptosis is known and brings into play a number of effectors such as proteases of the caspase family.
- IAP Inhibitors of apoptosis
- survivin a bifunctional protein, capable of simultaneously controlling the apoptosis of cells and of regulating their cell cycle.
- Survivin is a regulator of the survival and the resistance of the keratinocytes to the stresses that can induce this apoptosis phenomenon. It also regulates their capability for renewal and regeneration of the epidermis. It thus makes it possible to save the cellular capital of the epidermis and to maintain effective cell renewal (Dallaglio, et al., Experimental Dermatology, 18 (5) 464-72).
- the production of survivin is tightly controlled by the mitochondrial protein Smac/DIABLO (Second Mitochondrial Activator of Caspases or Direct IAP Binding Protein with Low pI), liberated during apoptosis.
- Smac/DIABLO Synthetic Mitochondrial Activator of Caspases or Direct IAP Binding Protein with Low pI
- UV radiation or free radicals such as the ROS induce cell stress in the skin, a stress which is involved in skin ageing.
- the mature mitochondrial protein Smac/DIABLO In response to stimuli such as UV radiation or reactive oxygen species (ROS), the mature mitochondrial protein Smac/DIABLO is released into the cell cytosol where it acts as an inhibitor of the IAP. In the form of dimers, it binds to the IAP and thus blocks the inactivation of the caspases (Kurita-Ochiai T et al, J. Dent. Res. 2010, 89(7), 689-694).
- an orchid extract exhibits such an inhibitory effect on the expression of the protein smac/DIABLO, and more particularly an extract of flowers of the orchid Dendrobium chtysotoxum.
- erianin has been isolated from an extract of stems of Dendrobium chtysotoxum (N G et al, Life Science, 2000, 66 (8), 709-23), a compound for which an antioxidant activity has been demonstrated in the rat.
- the principal purpose of the invention is to provide novel cosmetic compositions, intended in particular to prevent or delay the appearance of the signs of skin ageing, or to slow or attenuate the effects thereof, or else also to promote cell or tissue longevity, this activity being obtained in particular by inhibition of the expression and/or the activity of mitochondrial protein Smac/DIABLO.
- the inventors of the present invention have now demonstrated that the treatment of normal human keratinocytes (NHK) with at least one extract of an orchid of the species Dendrobium chrysotoxum , induces a significant decrease in the expression and/or the activity of the mitochondrial protein Smac/DIABLO.
- NHK normal human keratinocytes
- This effect of inhibition of the expression and/or the activity of said protein results in a more intense activity of limitation of apoptosis of the cells and regulation of their cell cycle by the IAPs.
- the invention relates to a cosmetic composition comprising said extract and to a cosmetic or dermatologic care method characterized in that it comprises the application of an effective quantity of a composition according to the invention onto the part of the skin of the face or the body concerned.
- the invention relates to an orchid extract, in particular of the species Dendrobium chrysotoxum , for preventing or delaying the appearance of the signs of skin ageing, or slowing or attenuating the effects thereof, or else also promoting cell or tissue longevity, in particular in that it inhibits the expression and/or the activity of the mitochondrial protein Smac/DIABLO (extract of the invention), and its use as an active agent in cosmetic or dermatologic compositions
- a first subject of the invention relates to a cosmetic composition, comprising at least one extract of flowers of the orchid Dendrobium chrysotoxum as an active agent and at least one cosmetically acceptable excipient.
- the cosmetic composition is more particularly intended to prevent or delay the appearance of the signs of skin ageing or to slow or attenuate the effects thereof, or else also to promote cell or tissue longevity.
- the extract of the invention advantageously inhibits the expression and/or the activity of the mitochondrial protein Smac/DIABLO.
- the plant material preferably consists only of flowers of the orchid Dendrobium chrysotoxum .
- the invention also relates to combinations of the extract of the invention with any extract of another part of the orchid Dendrobium chrysotoxum , preferably prepared under the same conditions as the extract of the invention, or compound isolated from one of these extracts.
- the extract of the invention can be prepared by different extraction processes known to those skilled in the art.
- the extract is obtained by means of a polar solvent or a mixture of polar solvents.
- a solvent or a mixture of solvents is advantageously selected from water, a C 1 -C 4 alcohol, for example ethanol, a C 2 -C 6 glycol, preferably selected from glycerol, butylene glycol and propylene glycol, or else also any mixture thereof.
- the C 1 -C 4 alcohol is ethanol.
- the plant material is extracted by means of a solvent comprising at least 50% v/v of ethanol and up to 100% v/v of ethanol, the balance if necessary consisting of another polar solvent and in particular of water.
- the extraction can be performed hot under reflux or else at ambient temperature.
- the extraction is effected by maceration of the plant material in a polar solvent or a mixture of polar solvents such as aforesaid, at ambient temperature for several hours.
- the extract is a dry extract, possibly brought into solution.
- the plant material Prior to the extraction step itself, the plant material may have been dried and/or ground and/or delipidated.
- the delipidation of the extract can be effected by means of nonpolar solvents, such as for example a C 6 -C 7 alkane, or else also by CO 2 in the supercritical state, possibly with the addition of a polar co-solvent such as ethanol, methanol or else caprylic/capric triglycerides (Mygliol 812®, Hüls AG).
- nonpolar solvents such as for example a C 6 -C 7 alkane
- CO 2 in the supercritical state
- a polar co-solvent such as ethanol, methanol or else caprylic/capric triglycerides (Mygliol 812®, Hüls AG).
- the extraction can also, optionally, comprise at least one supplementary stage of decolourization or purification of the extract of the invention.
- the decolourization of the extract can for example consist in a treatment of said extract with a nonpolar solvent of the type of those used to delipidate the extract.
- the extraction can be completed by a stage of partial or total removal of the extraction solvents.
- the extract is generally concentrated until an aqueous concentrate not containing a significant quantity of organic solvents is obtained, and in the second case a dry residue is obtained.
- the product from the extraction stage can be lyophilized or atomized to take the form of a powder.
- the extract is used in the dry state or else in solution or suspension in a solvent or a mixture of cosmetically acceptable solvents, which can be identical or different from that or those used for the extraction.
- the cosmetic composition comprises an effective quantity of extract for obtaining the desired effect, in particular an inhibition of the expression and/or of the activity of the mitochondrial protein Smac/DIABLO.
- the composition thus preferably comprises from 0.0001% to 1% by weight of dry extract, preferably from 0.001% to 0.01% by weight relative to the total weight of the composition.
- the properties of the extract of the invention can also be obtained or improved in cosmetic compositions wherein the extract of the invention is combined with other cosmetically acceptable active agents, in the form of purified substances and/or extracts, in particular plant extracts, exhibiting cosmetic effects similar and/or complementary to those of said extract of the invention.
- composition can thus comprise one or more other extracts of plants, and advantageously comprise at least one extract of another part of the orchid Dendrobium chrysotoxum or of another orchid or a substance purified from such an extract.
- the cosmetic composition can also advantageously comprise one or more other active agents among those which stimulate the expression of survivin such as forskolin or an extract containing these, in particular an extract of Coleus forskolii , or else also a plant extract obtained from a plant species selected from Nostoc commune, Butea frondasa, Neochloris oleabundans, Scenedesmus dimorphus, Curcuma longa, Crocus sativus, Daniellia oliveri, Lepechinia caulescens, Limnophila conferta , and any mixture thereof.
- active agents among those which stimulate the expression of survivin such as forskolin or an extract containing these, in particular an extract of Coleus forskolii , or else also a plant extract obtained from a plant species selected from Nostoc commune, Butea frondasa, Neochloris oleabundans, Scenedesmus dimorphus, Curcuma longa, Crocus sativus, Daniellia olive
- the cosmetic composition can comprise other cosmetically acceptable active agents selected from the group of substances having an anti-ageing activity, substances having a depigmenting, whitening or clearing activity on the skin, substances having a slimming activity, substances having a hydrating activity, substances having a calming, soothing or relaxing activity, substances having an activity stimulating the skin microcirculation to improve the lustre of the complexion, in particular of the face, substances having a sebo-regulatory activity for the care of oily skins, substances intended to clean or purify the skin, substances having an anti-radical activity, and any mixture thereof.
- other cosmetically acceptable active agents selected from the group of substances having an anti-ageing activity, substances having a depigmenting, whitening or clearing activity on the skin, substances having a slimming activity, substances having a hydrating activity, substances having a calming, soothing or relaxing activity, substances having an activity stimulating the skin microcirculation to improve the lustre of the complexion, in particular of the face, substances having a sebo-regulatory activity for the
- composition of the invention comprises at least one cosmetically acceptable excipient which may be selected from pigments, colorants, polymers, surface-active agents, viscosity agents, perfumes, electrolytes, pH adjusters, anti-oxidant agents, preservatives, and any mixture thereof.
- cosmetically acceptable excipient may be selected from pigments, colorants, polymers, surface-active agents, viscosity agents, perfumes, electrolytes, pH adjusters, anti-oxidant agents, preservatives, and any mixture thereof.
- the cosmetic composition can for example be a serum, a lotion, a cream, a hydrogel, preferably a mask, an oil-in-water emulsion, an anhydrous composition, or else be in the form of a stick, a patch, or in the form of a make-up product of the lipstick, mascara or foundation type.
- the extract and the composition of the invention exhibit a particularly desired effect for preventing or delaying the appearance of the signs of skin ageing or for slowing or attenuating the effects thereof, or else also for promoting cell or tissue longevity.
- a second subject of the invention thus relates to the use in a cosmetic composition of at least one extract of flowers of the orchid Dendrobium chrysotoxum as an active agent intended to prevent or delay the appearance of the signs of skin ageing or to slow or attenuate the effects thereof, or else also to promote cell or tissue longevity.
- the extract or the composition is as defined above or below.
- composition comprising said extract is itself intended to prevent or delay the appearance of the signs of skin ageing or to slow or attenuate the effects thereof, or else also to promote cell or tissue longevity.
- a third subject of the invention relates to a cosmetic care method, in particular for preventing or delaying the appearance of the signs of skin ageing or for slowing or attenuating the effects thereof, or else also for promoting cell or tissue longevity, characterized in that it comprises the application of an effective quantity of a cosmetic composition as defined above onto at least one part of the skin of the face or the body.
- the cosmetic composition is applied onto a skin zone of the body or the face exhibiting visible signs of ageing such as the presence of wrinkles or small wrinkles or a loss of lustre of the skin complexion, or other signs such as a loss of elasticity and/or suppleness of the skin, a decrease in the thickness of the skin, and/or an increase in skin dryness or roughness.
- the invention also relates to the use of an effective amount of at least one extract of flowers of the orchid Dendrobium chrysotoxum , for the preparation of a composition for preventing or delaying the appearance of the signs of intrinsic and/or extrinsic ageing of the skin, or for slowing down the effects thereof.
- the composition can be especially applied via topical application to at least one area of skin of an individual exhibiting visible signs of ageing such as the presence of wrinkles or small wrinkles or a loss of lustre of the skin complexion, or other signs such as a loss of elasticity and/or suppleness of the skin, a decrease in the thickness of the skin, and/or an increase in skin dryness or roughness.
- the composition is especially intended to be applied on the skin of an individual being over 35 years old, over 40 years old, over 45 years old, over 50 years old, over 55 years old or even over 60 years old.
- the composition can advantageously be applied on mature skins. It can be specifically intended to prevent or delay the appearance of the signs of ageing of the skin of the face and/or of the eyes.
- a fourth subject of the invention relates to an orchid extract, in particular of the species Dendrobium chrysotoxum , inhibiting the expression and/or the activity of the mitochondrial protein Smac/DIABLO.
- the extract is advantageously an extract of flowers of Dendrobium chrysotoxum as defined above.
- the extract is moreover advantageously obtained by means of a polar solvent or a mixture of polar solvents as described above.
- said extract is a dry extract, possibly brought into solution.
- FIG. 1 represents the level of expression of the mitochondrial protein Smac/DIABLO (expressed in pg/ ⁇ g total proteins), measured by an immuno-enzymatic method, after treatment of normal human keratinocytes (NHK) with one of the extracts prepared in Example 1 (S-1 to S-4) and compared with a solvent control (T-SO) and a positive control (T+). The percentages indicated correspond to the percentages inhibition relative to the solvent control (T-SO).
- the plant material of extracts S-1, S-2, 5-3 and 5-4 consisted of flowers of the orchid Dendrobium chrysotoxum .
- the extracts R and G were obtained from roots of the Dendrobium chrysotoxum orchid or from the leaves of the Grammatophyllum sp. orchid.
- the plant material in a dry state and ground, was subjected to an aqueous alcohol extraction with 90/10 v/v ethanol/water under reflux for 30 minutes in order to prepare extracts 5-1, R and G.
- the extraction solvent was then removed to obtain a dry extract.
- the extracts prepared and their associated extraction yield expressed as percentage (weight/weight) of dry extract relative to the starting plant material in the dry state and ground are summarized below.
- Extract code Type of extraction Extraction yield S-1 Ethanol/water 90/10 v/v - reflux 23.1% S-2 Ethanol 100% - reflux 17.0% S-3 Ethanol/water 70/30 v/v - AT 27.9% S-4 Ethanol/water 50/50 v/v - AT 28.4% R Ethanol/water 90/10 v/v - reflux 14.7% G Ethanol/water 90/10 v/v - reflux 14.1%
- Example 2 For the cosmetic activity tests of Example 2 below, a stock solution was prepared for each extract, in which the dry extract was dissolved in DMSO at the concentration of 12.5 mg of extract per mL of solvent.
- Forskolin is a known activator of the expression of survivin (cf. example 1 of the patent application FR2932086).
- an extract of Coleus forskolii which contains at the minimum 98% by weight of forskolin was used as the positive control.
- Such an extract is marketed in the form of powder for example by SIGMA.
- the solution of the positive control thus prepared was added to the culture medium so as to obtain a dilution to one thousandth, i.e. a forskolin concentration equal to about 10 ⁇ 9 M.
- DMSO solvent control
- the stock solution of each extract tested (S-1 to 5-4, R and G) was diluted in the keratinocyte culture medium in order to obtain a final concentration of extract of 12.5 ⁇ g/mL.
- the cultured NHK were inoculated into 48-well microplates in an amount of 50,000 cells per well, in complete serum-free culture medium (KSFMc, Gibco).
- This first culturing day corresponds to D0.
- the treatment stage started on D1, after 24 hours of incubation (37° C., 5% CO 2 ) of the NHK.
- the NHK were lysed on a half plate in order to perform the assays (lysis buffer prepared extemporaneously according to the protocol described in the Smac/DIABLO protein assay kit (ref. below).
- the other half plate was rinsed with PBS and then stored at ⁇ 20° C. in order to assay the total proteins therein by a colorimetric test according to the BCA method (BC Assay Kit, Uptima Interchim) by absorbance measurement at 570 nm.
- the level of Smac/DIABLO produced by the keratinocytes was evaluated with the Duoset Smac/DIABLO ELISA kit (R&D Systems).
- HRP horseradish peroxidase
- the absorbance was measurable at a wavelength of 450 nm.
- a standard range was created on the basis of dilutions of a standard stock solution of Smac/DIABLO, provided in the kit.
- the percentages inhibition of the production of this protein were calculated relative to the basal level without treatment (TSO).
- the positive control is forskolin (FSK).
- the root extract of Dendrobium chrysotoxum and the leaf extract of Grammatophyllum sp. do not have a significant inhibiting effect on the expression of the Smac/DIABLO protein.
- the difference in concentration in the protein with the DMSO indicator is no more than ⁇ 9% for the Dendrobium chrysotoxum root extract and ⁇ 13% for the Grammatophyllum sp. leaf extract.
- the extracts of the invention which can be obtained by extraction processes using polar solvents, were formulated as anti-ageing active agents in cosmetic compositions, and in particular for preventing or delaying the appearance of the signs of skin ageing or for slowing or attenuating the effects, or else also for promoting cell or tissue longevity.
- the dry extract was dissolved at 2% w/w in a 60/40 v/v glycerol/water mixture.
- Pentylene glycol 3 Glyceryl stearate 3
- Cetyl alcohol 1 Stearyl alcohol 1 Dimethicone 1
- phase A The excipients of phase A were dispersed in water, then heated to 80° C., before dissolving all the other compounds including the water-glycol solution of Dendrobium chrysotoxum extract.
- phase B The compounds of phase B were heated to 85° C. to form a homogeneous phase.
- Phase A was emulsified in phase B by means of an Ystral mixer.
- phase C the oil-in-water emulsion thus obtained was neutralized by means of a 0.04% w/w solution of sodium hydroxide (phase C), then cooled.
- composition obtained is an anti-ageing cream intended to be applied onto all or part of the face.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cosmetics (AREA)
Abstract
The invention relates to a cosmetic composition comprising at least one extract from the orchid Dendrobium chrysotoxum as an active agent and at least one cosmetically acceptable excipient.
The invention relates to the use in a cosmetic composition of an extract from the orchid Dendrobium chrysotoxum as an active agent for preventing or delaying the appearance of the signs of skin ageing or for slowing or attenuating the effects thereof, or else also for promoting cell or tissue longevity.
The invention in particular relates to an orchid extract inhibiting the expression and/or the activity of the mitochondrial protein Smac/DIABLO.
Description
- The invention relates to a novel cosmetic composition, comprising at least one extract from the orchid Dendrobium chrysotoxum as an active agent and at least one cosmetically acceptable excipient, in particular for preventing or delaying the appearance of the signs of skin ageing, for slowing or attenuating the effects thereof, or else also for promoting cell or tissue longevity.
- Skin ageing reveals itself in numerous changes intrinsic to the skin and the progressive appearance of visible signs which modify the beauty and the quality of the skin. The skin texture is less fine, and numerous skin blemishes develop.
- At the cellular level, the ageing results in a progressive deterioration in biological mechanisms such as the slowing of the synthesis of structural proteins (collagen, elastin).
- Apoptosis, a type of programmed cell death, is an active biological process of elimination of cells from the body, by fragmentation and under genetic control.
- The elimination can be natural (surplus cells in a tissue) or induced by various stresses.
- The biological cascade of apoptosis is known and brings into play a number of effectors such as proteases of the caspase family.
- Inhibitors of apoptosis (IAP) are known, having the function of blocking the activation of pro-caspases and inhibiting the activity of mature caspases, which results in slowing of the phenomenon of apoptosis (Deveraux et al, Genes Dev. 13 (1999), pp. 239-25.
- Among the IAP, mention is made of survivin, a bifunctional protein, capable of simultaneously controlling the apoptosis of cells and of regulating their cell cycle.
- Survivin is a regulator of the survival and the resistance of the keratinocytes to the stresses that can induce this apoptosis phenomenon. It also regulates their capability for renewal and regeneration of the epidermis. It thus makes it possible to save the cellular capital of the epidermis and to maintain effective cell renewal (Dallaglio, et al., Experimental Dermatology, 18 (5) 464-72).
- The production of survivin is tightly controlled by the mitochondrial protein Smac/DIABLO (Second Mitochondrial Activator of Caspases or Direct IAP Binding Protein with Low pI), liberated during apoptosis.
- This protein, Smac/DIABLO, synthesized in the form of a 29 kDa precursor, is translocated in the mitochondrion by its N-terminal domain which possesses a mitochondrial location signal. This precursor is then cleaved to give rise to a 23 kDa mature protein (Zhang et al, Acta Siochim. Biophys. Sin. 2007, 39 (2), 108-116).
- It is known that UV radiation or free radicals such as the ROS induce cell stress in the skin, a stress which is involved in skin ageing.
- In response to stimuli such as UV radiation or reactive oxygen species (ROS), the mature mitochondrial protein Smac/DIABLO is released into the cell cytosol where it acts as an inhibitor of the IAP. In the form of dimers, it binds to the IAP and thus blocks the inactivation of the caspases (Kurita-Ochiai T et al, J. Dent. Res. 2010, 89(7), 689-694).
- Similarly, in response to these same stimuli, reduced production of Smac/DIABLO has been demonstrated, concomitantly with overexpression of survivin which increases cell longevity (Aziz M H. et al, Photochem. Photobiol. 2005, 81(1), 25-31).
- It is thus of particular interest, in order to combat skin ageing more effectively, to be able to have available in cosmetics one or more other active agents capable of significantly reducing the expression and/or the activity of this protein Smac/DIABLO in the cells of the epidermis and to allow the IAP to inhibit the caspases in such a way as to improve cell reactivity towards the stress induced by UV radiation or free radicals and to promote cell longevity.
- However, until now, such agents for cosmetic applications have never been described.
- It is thus particularly surprising to have demonstrated that an orchid extract exhibits such an inhibitory effect on the expression of the protein smac/DIABLO, and more particularly an extract of flowers of the orchid Dendrobium chtysotoxum.
- Among the orchids, several species belonging to the genus Dendrobium are known in traditional Chinese medicine. However, it is the extracts of stems or leaves which are used (Gutierrez R M P, J. Med. Plant Res., 2010, 4 (8), 592-638).
- In particular, erianin has been isolated from an extract of stems of Dendrobium chtysotoxum (N G et al, Life Science, 2000, 66 (8), 709-23), a compound for which an antioxidant activity has been demonstrated in the rat.
- Until now, no particular activity has ever been demonstrated for an extract of flowers of Dendrobium chtysotoxum.
- The principal purpose of the invention is to provide novel cosmetic compositions, intended in particular to prevent or delay the appearance of the signs of skin ageing, or to slow or attenuate the effects thereof, or else also to promote cell or tissue longevity, this activity being obtained in particular by inhibition of the expression and/or the activity of mitochondrial protein Smac/DIABLO.
- It is also a purpose of the invention to provide a cosmetic care method using said cosmetic compositions.
- It is also a purpose of the invention to provide a novel extract of plant origin reducing the expression and/or the activity of the mitochondrial protein Smac/DIABLO, in the skin and in particular in the epidermis.
- Finally, it is a purpose of the invention to solve the totality of the technical problems by a simple, relatively low cost solution, usable on the industrial scale, in particular in the cosmetics industry.
- The inventors of the present invention have now demonstrated that the treatment of normal human keratinocytes (NHK) with at least one extract of an orchid of the species Dendrobium chrysotoxum, induces a significant decrease in the expression and/or the activity of the mitochondrial protein Smac/DIABLO.
- This effect of inhibition of the expression and/or the activity of said protein results in a more intense activity of limitation of apoptosis of the cells and regulation of their cell cycle by the IAPs.
- Thus, according to a first aspect, the invention relates to a cosmetic composition comprising said extract and to a cosmetic or dermatologic care method characterized in that it comprises the application of an effective quantity of a composition according to the invention onto the part of the skin of the face or the body concerned.
- According to a second aspect, the invention relates to an orchid extract, in particular of the species Dendrobium chrysotoxum, for preventing or delaying the appearance of the signs of skin ageing, or slowing or attenuating the effects thereof, or else also promoting cell or tissue longevity, in particular in that it inhibits the expression and/or the activity of the mitochondrial protein Smac/DIABLO (extract of the invention), and its use as an active agent in cosmetic or dermatologic compositions
- A first subject of the invention relates to a cosmetic composition, comprising at least one extract of flowers of the orchid Dendrobium chrysotoxum as an active agent and at least one cosmetically acceptable excipient.
- The cosmetic composition is more particularly intended to prevent or delay the appearance of the signs of skin ageing or to slow or attenuate the effects thereof, or else also to promote cell or tissue longevity.
- The extract of the invention advantageously inhibits the expression and/or the activity of the mitochondrial protein Smac/DIABLO.
- The plant material preferably consists only of flowers of the orchid Dendrobium chrysotoxum. However, the invention also relates to combinations of the extract of the invention with any extract of another part of the orchid Dendrobium chrysotoxum, preferably prepared under the same conditions as the extract of the invention, or compound isolated from one of these extracts.
- The extract of the invention can be prepared by different extraction processes known to those skilled in the art.
- Advantageously the extract is obtained by means of a polar solvent or a mixture of polar solvents.
- As the polar solvent, a solvent or a mixture of solvents is advantageously selected from water, a C1-C4 alcohol, for example ethanol, a C2-C6 glycol, preferably selected from glycerol, butylene glycol and propylene glycol, or else also any mixture thereof.
- According to a preferred embodiment, the C1-C4 alcohol is ethanol.
- In particular, the plant material is extracted by means of a solvent comprising at least 50% v/v of ethanol and up to 100% v/v of ethanol, the balance if necessary consisting of another polar solvent and in particular of water.
- The extraction can be performed hot under reflux or else at ambient temperature.
- According to a preferred modification of the invention, the extraction is effected by maceration of the plant material in a polar solvent or a mixture of polar solvents such as aforesaid, at ambient temperature for several hours.
- According to one modification, the extract is a dry extract, possibly brought into solution.
- Prior to the extraction step itself, the plant material may have been dried and/or ground and/or delipidated.
- The delipidation of the extract can be effected by means of nonpolar solvents, such as for example a C6-C7 alkane, or else also by CO2 in the supercritical state, possibly with the addition of a polar co-solvent such as ethanol, methanol or else caprylic/capric triglycerides (Mygliol 812®, Hüls AG).
- The extraction can also, optionally, comprise at least one supplementary stage of decolourization or purification of the extract of the invention.
- The decolourization of the extract can for example consist in a treatment of said extract with a nonpolar solvent of the type of those used to delipidate the extract.
- The extraction can be completed by a stage of partial or total removal of the extraction solvents.
- In the first case, the extract is generally concentrated until an aqueous concentrate not containing a significant quantity of organic solvents is obtained, and in the second case a dry residue is obtained.
- Alternatively, the product from the extraction stage can be lyophilized or atomized to take the form of a powder.
- As an active agent in the cosmetic composition according to the invention, the extract is used in the dry state or else in solution or suspension in a solvent or a mixture of cosmetically acceptable solvents, which can be identical or different from that or those used for the extraction.
- The cosmetic composition comprises an effective quantity of extract for obtaining the desired effect, in particular an inhibition of the expression and/or of the activity of the mitochondrial protein Smac/DIABLO.
- The composition thus preferably comprises from 0.0001% to 1% by weight of dry extract, preferably from 0.001% to 0.01% by weight relative to the total weight of the composition.
- The properties of the extract of the invention can also be obtained or improved in cosmetic compositions wherein the extract of the invention is combined with other cosmetically acceptable active agents, in the form of purified substances and/or extracts, in particular plant extracts, exhibiting cosmetic effects similar and/or complementary to those of said extract of the invention.
- The composition can thus comprise one or more other extracts of plants, and advantageously comprise at least one extract of another part of the orchid Dendrobium chrysotoxum or of another orchid or a substance purified from such an extract.
- The cosmetic composition can also advantageously comprise one or more other active agents among those which stimulate the expression of survivin such as forskolin or an extract containing these, in particular an extract of Coleus forskolii, or else also a plant extract obtained from a plant species selected from Nostoc commune, Butea frondasa, Neochloris oleabundans, Scenedesmus dimorphus, Curcuma longa, Crocus sativus, Daniellia oliveri, Lepechinia caulescens, Limnophila conferta, and any mixture thereof.
- Finally, the cosmetic composition can comprise other cosmetically acceptable active agents selected from the group of substances having an anti-ageing activity, substances having a depigmenting, whitening or clearing activity on the skin, substances having a slimming activity, substances having a hydrating activity, substances having a calming, soothing or relaxing activity, substances having an activity stimulating the skin microcirculation to improve the lustre of the complexion, in particular of the face, substances having a sebo-regulatory activity for the care of oily skins, substances intended to clean or purify the skin, substances having an anti-radical activity, and any mixture thereof.
- Advantageously, the composition of the invention comprises at least one cosmetically acceptable excipient which may be selected from pigments, colorants, polymers, surface-active agents, viscosity agents, perfumes, electrolytes, pH adjusters, anti-oxidant agents, preservatives, and any mixture thereof.
- The cosmetic composition can for example be a serum, a lotion, a cream, a hydrogel, preferably a mask, an oil-in-water emulsion, an anhydrous composition, or else be in the form of a stick, a patch, or in the form of a make-up product of the lipstick, mascara or foundation type.
- The extract and the composition of the invention exhibit a particularly desired effect for preventing or delaying the appearance of the signs of skin ageing or for slowing or attenuating the effects thereof, or else also for promoting cell or tissue longevity.
- A second subject of the invention thus relates to the use in a cosmetic composition of at least one extract of flowers of the orchid Dendrobium chrysotoxum as an active agent intended to prevent or delay the appearance of the signs of skin ageing or to slow or attenuate the effects thereof, or else also to promote cell or tissue longevity.
- Advantageously, the extract or the composition is as defined above or below.
- Advantageously, the composition comprising said extract is itself intended to prevent or delay the appearance of the signs of skin ageing or to slow or attenuate the effects thereof, or else also to promote cell or tissue longevity.
- A third subject of the invention relates to a cosmetic care method, in particular for preventing or delaying the appearance of the signs of skin ageing or for slowing or attenuating the effects thereof, or else also for promoting cell or tissue longevity, characterized in that it comprises the application of an effective quantity of a cosmetic composition as defined above onto at least one part of the skin of the face or the body.
- Advantageously, the cosmetic composition is applied onto a skin zone of the body or the face exhibiting visible signs of ageing such as the presence of wrinkles or small wrinkles or a loss of lustre of the skin complexion, or other signs such as a loss of elasticity and/or suppleness of the skin, a decrease in the thickness of the skin, and/or an increase in skin dryness or roughness.
- The invention also relates to the use of an effective amount of at least one extract of flowers of the orchid Dendrobium chrysotoxum, for the preparation of a composition for preventing or delaying the appearance of the signs of intrinsic and/or extrinsic ageing of the skin, or for slowing down the effects thereof. The composition can be especially applied via topical application to at least one area of skin of an individual exhibiting visible signs of ageing such as the presence of wrinkles or small wrinkles or a loss of lustre of the skin complexion, or other signs such as a loss of elasticity and/or suppleness of the skin, a decrease in the thickness of the skin, and/or an increase in skin dryness or roughness. The composition is especially intended to be applied on the skin of an individual being over 35 years old, over 40 years old, over 45 years old, over 50 years old, over 55 years old or even over 60 years old. The composition can advantageously be applied on mature skins. It can be specifically intended to prevent or delay the appearance of the signs of ageing of the skin of the face and/or of the eyes.
- A fourth subject of the invention relates to an orchid extract, in particular of the species Dendrobium chrysotoxum, inhibiting the expression and/or the activity of the mitochondrial protein Smac/DIABLO.
- The extract is advantageously an extract of flowers of Dendrobium chrysotoxum as defined above.
- The extract is moreover advantageously obtained by means of a polar solvent or a mixture of polar solvents as described above.
- Preferably, said extract is a dry extract, possibly brought into solution.
- Other purposes, characteristics and advantages of the invention will appear clearly in the light of the explanatory description which follows, made with reference to examples of extract preparation and tests demonstrating the properties of the extract and to examples of a cosmetic composition using such an extract, which are given by way of illustration of the invention without however limiting the scope thereof.
- In the examples, all the percentages are given by weight, the temperature is in degrees Celsius and the pressure is atmospheric pressure, unless otherwise indicated.
-
FIG. 1 represents the level of expression of the mitochondrial protein Smac/DIABLO (expressed in pg/μg total proteins), measured by an immuno-enzymatic method, after treatment of normal human keratinocytes (NHK) with one of the extracts prepared in Example 1 (S-1 to S-4) and compared with a solvent control (T-SO) and a positive control (T+). The percentages indicated correspond to the percentages inhibition relative to the solvent control (T-SO). - Preparation of the Extracts of the Invention
- Four extracts as well as two other extracts serving as a comparison were prepared according to the invention.
- The plant material of extracts S-1, S-2, 5-3 and 5-4 consisted of flowers of the orchid Dendrobium chrysotoxum. The extracts R and G were obtained from roots of the Dendrobium chrysotoxum orchid or from the leaves of the Grammatophyllum sp. orchid.
- The plant material, in a dry state and ground, was subjected to an aqueous alcohol extraction with 90/10 v/v ethanol/water under reflux for 30 minutes in order to prepare extracts 5-1, R and G. The extraction solvent was then removed to obtain a dry extract.
- The above extraction was reproduced to obtain the extracts S-2, S-3 and S-4 changing the extraction solvent and the temperature conditions. Two extraction temperatures were tested: ambient temperature (AT) for 16 hours, or else hot (solvent reflux) for at least 30 minutes.
- The extracts prepared and their associated extraction yield expressed as percentage (weight/weight) of dry extract relative to the starting plant material in the dry state and ground are summarized below.
-
Extract code Type of extraction Extraction yield S-1 Ethanol/water 90/10 v/v - reflux 23.1% S-2 Ethanol 100% - reflux 17.0% S-3 Ethanol/water 70/30 v/v - AT 27.9% S-4 Ethanol/water 50/50 v/v - AT 28.4% R Ethanol/water 90/10 v/v - reflux 14.7% G Ethanol/water 90/10 v/v - reflux 14.1% - For the cosmetic activity tests of Example 2 below, a stock solution was prepared for each extract, in which the dry extract was dissolved in DMSO at the concentration of 12.5 mg of extract per mL of solvent.
- 2.1—Preparation of the Positive Control and Solutions of Extracts
- Forskolin is a known activator of the expression of survivin (cf. example 1 of the patent application FR2932086).
- For the test below, an extract of Coleus forskolii which contains at the minimum 98% by weight of forskolin was used as the positive control. Such an extract is marketed in the form of powder for example by SIGMA.
- The extract powder was dissolved in DMSO so as to obtain a forskolin concentration (molar mass=410.5) of about 10−6 M.
- The solution of the positive control thus prepared was added to the culture medium so as to obtain a dilution to one thousandth, i.e. a forskolin concentration equal to about 10−9 M.
- In parallel, a solvent control (DMSO), diluted to one thousandth in the culture medium, was prepared.
- The stock solution of each extract tested (S-1 to 5-4, R and G) was diluted in the keratinocyte culture medium in order to obtain a final concentration of extract of 12.5 μg/mL.
- 2.2—Treatment of the NHK
- The cultured NHK were inoculated into 48-well microplates in an amount of 50,000 cells per well, in complete serum-free culture medium (KSFMc, Gibco).
- This first culturing day corresponds to D0.
- The treatment stage started on D1, after 24 hours of incubation (37° C., 5% CO2) of the NHK.
- After removal of the culture medium, this was replaced by new KSFMc medium containing either the extract to be tested or the positive control or else the solvent control (T-SO). Each treatment was effected in triplicate.
- After 16 hours of treatment, a period corresponding to the expression peak of survivin in the course of the cell cycle, the NHK were lysed on a half plate in order to perform the assays (lysis buffer prepared extemporaneously according to the protocol described in the Smac/DIABLO protein assay kit (ref. below). The other half plate was rinsed with PBS and then stored at −20° C. in order to assay the total proteins therein by a colorimetric test according to the BCA method (BC Assay Kit, Uptima Interchim) by absorbance measurement at 570 nm.
- 2.3 Assay method
- The level of Smac/DIABLO produced by the keratinocytes was evaluated with the Duoset Smac/DIABLO ELISA kit (R&D Systems).
- The addition of a streptavidin coupled to a chromophore, here HRP (horseradish peroxidase), made it possible to evaluate the enzymatic activity of the latter by addition of its substrate (tetramethylbenzidine) in the presence of hydrogen peroxide.
- Once the enzymatic reaction was blocked with sulphuric acid, the presence of Smac/DIABLO was revealed via the colorimetric reaction, proportional to its concentration.
- The absorbance was measurable at a wavelength of 450 nm.
- A standard range was created on the basis of dilutions of a standard stock solution of Smac/DIABLO, provided in the kit.
- 2.4—Results of the Assay of the Smac/DIABLO Protein in NHK Lysates
- The results are shown in
FIG. 1 . They are expressed in pg of Smac/DIABLO protein per μg of total proteins (pg/μg prot.). - The percentages inhibition of the production of this protein were calculated relative to the basal level without treatment (TSO). The positive control is forskolin (FSK).
- Each of the four extracts of the invention tested exhibited significant activity (S-1: −39%; S-2: −54%; S-3: −39%; S-4: −29%) in reducing the expression of the mitochondrial protein Smac/DIABLO in the NHK, with an efficiency which can be greater than that of the positive control.
- By contrast, the root extract of Dendrobium chrysotoxum and the leaf extract of Grammatophyllum sp. do not have a significant inhibiting effect on the expression of the Smac/DIABLO protein. The difference in concentration in the protein with the DMSO indicator is no more than −9% for the Dendrobium chrysotoxum root extract and −13% for the Grammatophyllum sp. leaf extract.
- The extracts of the invention which can be obtained by extraction processes using polar solvents, were formulated as anti-ageing active agents in cosmetic compositions, and in particular for preventing or delaying the appearance of the signs of skin ageing or for slowing or attenuating the effects, or else also for promoting cell or tissue longevity.
- The extract of flowers of Dendrobium chrysotoxum used as an active agent in this cosmetic composition was obtained by reproducing the process of Example 1 (extract S-1).
- The dry extract was dissolved at 2% w/w in a 60/40 v/v glycerol/water mixture.
- This solution of extract was used as an active agent for the preparation of the cosmetic composition below (% expressed by weight relative to the final composition):
-
Phase A 2% solution of Dendrobium chrysotoxum extract 1 Phenoxyethanol 0.5 Xanthan gum 0.2 Acrylates/C20-30 alkylacrylate crosspolymers 0.2 Tetrasodium EDTA 0.1 Water qs qs: quantity sufficient to dissolve the compounds of phase A. -
Phase B Hydrogenated polyisobutene 4 Squalane 3 Caprylic/ capric triglycerides 3 Pentylene glycol 3 Glyceryl stearate 3 PEG-100 stearate 2.5 Beeswax 1.5 Dicaprylyl carbonate 1.5 Cetyl alcohol 1 Stearyl alcohol 1 Dimethicone 1 -
Phase C Sodium hydroxide 0.04 Water qs 100 qs 100: quantity sufficient for 100% of the final composition - The excipients of phase A were dispersed in water, then heated to 80° C., before dissolving all the other compounds including the water-glycol solution of Dendrobium chrysotoxum extract.
- The compounds of phase B were heated to 85° C. to form a homogeneous phase.
- Phase A was emulsified in phase B by means of an Ystral mixer.
- Finally, the oil-in-water emulsion thus obtained was neutralized by means of a 0.04% w/w solution of sodium hydroxide (phase C), then cooled.
- The composition obtained is an anti-ageing cream intended to be applied onto all or part of the face.
Claims (15)
1. Cosmetic composition comprising at least one extract of flowers of the orchid Dendrobium chrysotoxum as an active agent and at least one cosmetically acceptable excipient.
2. Cosmetic composition according to claim 1 , wherein said extract inhibits the expression and/or the activity of the mitochondrial protein Smac/DIABLO.
3. Cosmetic composition according to claim 1 , wherein said extract is obtained by means of a polar solvent or a mixture of polar solvents, advantageously selected from water, a C1-C4 alcohol, preferably ethanol, a C2-C6 glycol, preferably selected from glycerol, butylene glycol and propylene glycol, or else also any mixture thereof.
4. Cosmetic composition according to claim 1 , wherein said extract is obtained by means of a solvent comprising at least 50% v/v of ethanol and up to 100% v/v of ethanol, the balance if necessary consisting of another polar solvent and in particular of water.
5. Cosmetic composition according to claim 1 , wherein it comprises from 0.0001% to 1% by weight of dry extract, preferably from 0.001% to 0.01% by weight of dry extract relative to the total weight of the composition.
6. Cosmetic composition according to claim 1 , wherein it comprises a combination of the extract of flowers of the orchid Dendrobium chrysotoxum with other cosmetically acceptable active agents, in the form of purified substances and/or extracts, in particular plant extracts.
7. Cosmetic composition according to claim 1 , wherein it comprises at least one extract of another part of the orchid Dendrobium chrysotoxum or of another orchid or a substance purified from such an extract.
8. Cosmetic composition according to claim 1 , wherein it comprises one or more other active agents among those which stimulate the expression and/or the activity of survivin such as forskolin or an extract containing these, in particular an extract of Coleus forskolii, or else also a plant extract obtained from a plant species selected from Nostoc commune, Butea frondosa, Neochloris oleabundans, Scenedesmus dimorphus, Curcuma longa, Crocus sativus, Daniellia oliveri; Lepechinia caulescens, Limnophila conferta, and any mixture thereof.
9. Cosmetic composition according to claim 1 , wherein the acceptable cosmetic excipient is chosen among pigments, colorants, polymers, surfactants, rheological agents, perfumes, electrolytes, pH adjusters, antioxidant agents, preservatives and any one of their mixtures.
10. Use of at least one extract of flowers of the orchid Dendrobium chrysotoxum, in a cosmetic composition, as an active agent intended to prevent or delay the appearance of the signs of skin ageing or to slow or attenuate the effects thereof, or else also to promote cell or tissue longevity.
11. Use according to claim 10 , wherein the composition is itself intended to prevent or delay the appearance of the signs of skin ageing or to slow or attenuate the effects thereof, or else also to promote cell or tissue longevity.
12. A method of treatment for preventing or delaying the appearance of the signs of skin ageing or for slowing or attenuating the effects thereof, or else also for promoting cell or tissue longevity, comprising applying onto at least one part of the skin of the face or the body of a subject in need thereof, an effective amount of a composition according to claim 1 .
13. A method of treatment according to claim 12 , wherein said cosmetic composition is applied onto a skin zone of the body or the face exhibiting visible signs of ageing such as the presence of wrinkles or small wrinkles or a loss of lustre of the skin complexion, or other signs such as a loss of elasticity and/or suppleness of the skin, a decrease in the thickness of the skin, and/or an increase in skin dryness or roughness.
14. Orchid flower extract, in particular of the species Dendrobium chrysotoxum, inhibiting the expression and/or the activity of the mitochondrial protein Smac/DIABLO.
15. Orchid extract according to claim 14 , wherein said extract is obtained by means of a polar solvent or a mixture of polar solvents.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/836,322 US10172785B2 (en) | 2010-09-14 | 2015-08-26 | Dendrobium chrysotoxum extract and its cosmetic use as an anti-aging agent |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1057336A FR2964567B1 (en) | 2010-09-14 | 2010-09-14 | ORCHID EXTRACT |
FR1057336 | 2010-09-14 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/836,322 Division US10172785B2 (en) | 2010-09-14 | 2015-08-26 | Dendrobium chrysotoxum extract and its cosmetic use as an anti-aging agent |
Publications (1)
Publication Number | Publication Date |
---|---|
US20120064021A1 true US20120064021A1 (en) | 2012-03-15 |
Family
ID=43430793
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/231,466 Abandoned US20120064021A1 (en) | 2010-09-14 | 2011-09-13 | Dendrobium chysotoxum extract and its cosmetic use as an anti-aging agent |
US14/836,322 Expired - Fee Related US10172785B2 (en) | 2010-09-14 | 2015-08-26 | Dendrobium chrysotoxum extract and its cosmetic use as an anti-aging agent |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/836,322 Expired - Fee Related US10172785B2 (en) | 2010-09-14 | 2015-08-26 | Dendrobium chrysotoxum extract and its cosmetic use as an anti-aging agent |
Country Status (8)
Country | Link |
---|---|
US (2) | US20120064021A1 (en) |
JP (1) | JP5900845B2 (en) |
KR (1) | KR101932766B1 (en) |
CN (1) | CN102397184B (en) |
DE (1) | DE102011053521A1 (en) |
FR (1) | FR2964567B1 (en) |
GB (1) | GB2483766B (en) |
IT (1) | ITTO20110816A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013040395A2 (en) * | 2011-09-14 | 2013-03-21 | Nefeli Corp. | Herbal skin care composition |
US10144952B2 (en) | 2013-03-18 | 2018-12-04 | Qiagen Gmbh | Stabilization and isolation of extracellular nucleic acids |
US10676780B2 (en) | 2011-09-26 | 2020-06-09 | Qiagen Gmbh | Stabilisation and isolation of extracellular nucleic acids |
US10724074B2 (en) | 2012-09-25 | 2020-07-28 | Qiagen Gmbh | Stabilisation of biological samples |
US11021733B2 (en) | 2011-09-26 | 2021-06-01 | Qiagen Gmbh | Stabilization and isolation of extracellular nucleic acids |
US11203777B2 (en) | 2015-11-20 | 2021-12-21 | Qiagen Gmbh | Method of preparing sterilized compositions for stabilization of extracellular nucleic acids |
CN114081853A (en) * | 2021-03-26 | 2022-02-25 | 太和康美(北京)中医研究院有限公司 | Plant composition and preparation method and application thereof |
US11525155B2 (en) | 2013-03-18 | 2022-12-13 | Qiagen Gmbh | Stabilisation of biological samples |
US12110533B2 (en) | 2011-09-26 | 2024-10-08 | Qiagen Gmbh | Stabilisation and isolation of extracellular nucleic acids |
US12139744B2 (en) | 2013-03-18 | 2024-11-12 | Qiagen Gmbh | Stabilisation of biological samples |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN2015MN00022A (en) | 2012-07-26 | 2015-10-16 | Olive Medical Corp | |
CN103239471A (en) * | 2013-05-21 | 2013-08-14 | 广州中医药大学 | External preparation for skin moistening |
CN105853289A (en) * | 2016-05-05 | 2016-08-17 | 广州丹奇日用化工厂有限公司 | Cosmetic composition containing dendrobium extract and application of cosmetic composition |
CN106691949A (en) * | 2017-02-27 | 2017-05-24 | 广东黑霸生物科技有限公司 | Traditional Chinese medicine extract liquid having hair blackening effect, and preparation method and application thereof |
CN109875937A (en) * | 2017-12-06 | 2019-06-14 | 伽蓝(集团)股份有限公司 | The application of Herba Dendrobii extract |
CN108042458B (en) * | 2018-01-10 | 2021-11-23 | 中国科学院昆明植物研究所 | Dendrobium candidum extract and application thereof in preparation of cosmetics |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02279618A (en) * | 1989-04-20 | 1990-11-15 | Ichimaru Pharcos Co Ltd | Cosmetic containing extract of plant of family orchidaceae |
JP4880816B2 (en) * | 2000-12-15 | 2012-02-22 | 株式会社ヤクルト本社 | Skin anti-aging agent |
JP2002205933A (en) * | 2001-01-05 | 2002-07-23 | Ichimaru Pharcos Co Ltd | Cosmetic composition containing extract of orchidaceous plant |
DE102004010645A1 (en) * | 2003-04-24 | 2004-11-11 | Coty B.V. | Cosmetic for depigmentation |
US20070086972A1 (en) | 2005-09-12 | 2007-04-19 | Jacob Birnbaum | Hair growth compositions and methods for treating hair loss or related conditions |
FR2924348B1 (en) * | 2007-11-30 | 2010-11-26 | Lvmh Rech | COMPOSITION CONTAINING EXTRACT FROM ORCHID VANDA TERES. |
FR2928549B1 (en) * | 2008-03-13 | 2013-07-26 | Lvmh Rech | USE OF AN EXTRACT OF BRASSOCATTLEYA MARCELLA KOSS ORCHIDEE AS AN AGENT TO PREVENT OR DELAY THE APPEARANCE OF SIGNS OF SKIN AGING |
FR2932086A1 (en) * | 2008-06-06 | 2009-12-11 | Lvmh Rech | ANTI-AGE COSMETIC CARE METHOD BY STIMULATING THE EXPRESSION OF SURVIVAL |
-
2010
- 2010-09-14 FR FR1057336A patent/FR2964567B1/en not_active Expired - Fee Related
-
2011
- 2011-09-06 JP JP2011194093A patent/JP5900845B2/en not_active Expired - Fee Related
- 2011-09-07 KR KR1020110090611A patent/KR101932766B1/en active IP Right Grant
- 2011-09-08 GB GB1115497.8A patent/GB2483766B/en not_active Expired - Fee Related
- 2011-09-12 DE DE102011053521A patent/DE102011053521A1/en not_active Withdrawn
- 2011-09-13 US US13/231,466 patent/US20120064021A1/en not_active Abandoned
- 2011-09-13 IT IT000816A patent/ITTO20110816A1/en unknown
- 2011-09-14 CN CN201110270954.0A patent/CN102397184B/en not_active Expired - Fee Related
-
2015
- 2015-08-26 US US14/836,322 patent/US10172785B2/en not_active Expired - Fee Related
Non-Patent Citations (5)
Title |
---|
"Can we prevent aging". Retrieved from the Internet on: 2012-11-16. Retrieved from: . * |
(U1) forskolin 2005http://web.archive.org/web/20051024120013/http://www.advance-health.com/coleus.html * |
Brannon, H. Retrieved from the Internet on: 2012-12-03. Retrieved from:. * |
Sastre et al.The Role of Mitochondrial Oxidative Stress in Aging, 2003, Free Radic Biol Med, 35: 1-8 * |
Stibich, Mark. "Free Radical Theory of Aging". Web Update date: 2014-08-14 [Retrieved from the internet on: 2015-03-21]. Retrieved from: . * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013040395A3 (en) * | 2011-09-14 | 2013-05-10 | Nefeli Corp. | Herbal skin care composition |
US9192643B2 (en) | 2011-09-14 | 2015-11-24 | Nefeli Corp. | Herbal skin care composition |
US9272012B1 (en) | 2011-09-14 | 2016-03-01 | Nefeli Corp. | Herbal skin care composition |
WO2013040395A2 (en) * | 2011-09-14 | 2013-03-21 | Nefeli Corp. | Herbal skin care composition |
US11021733B2 (en) | 2011-09-26 | 2021-06-01 | Qiagen Gmbh | Stabilization and isolation of extracellular nucleic acids |
US12110533B2 (en) | 2011-09-26 | 2024-10-08 | Qiagen Gmbh | Stabilisation and isolation of extracellular nucleic acids |
US10676780B2 (en) | 2011-09-26 | 2020-06-09 | Qiagen Gmbh | Stabilisation and isolation of extracellular nucleic acids |
US10724074B2 (en) | 2012-09-25 | 2020-07-28 | Qiagen Gmbh | Stabilisation of biological samples |
US11525155B2 (en) | 2013-03-18 | 2022-12-13 | Qiagen Gmbh | Stabilisation of biological samples |
US10144952B2 (en) | 2013-03-18 | 2018-12-04 | Qiagen Gmbh | Stabilization and isolation of extracellular nucleic acids |
US12139744B2 (en) | 2013-03-18 | 2024-11-12 | Qiagen Gmbh | Stabilisation of biological samples |
US11203777B2 (en) | 2015-11-20 | 2021-12-21 | Qiagen Gmbh | Method of preparing sterilized compositions for stabilization of extracellular nucleic acids |
CN114081853A (en) * | 2021-03-26 | 2022-02-25 | 太和康美(北京)中医研究院有限公司 | Plant composition and preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN102397184B (en) | 2016-02-03 |
US20150359733A1 (en) | 2015-12-17 |
JP5900845B2 (en) | 2016-04-06 |
FR2964567A1 (en) | 2012-03-16 |
GB2483766B (en) | 2013-02-13 |
GB201115497D0 (en) | 2011-10-26 |
JP2012067098A (en) | 2012-04-05 |
KR20120028238A (en) | 2012-03-22 |
ITTO20110816A1 (en) | 2012-03-15 |
GB2483766A (en) | 2012-03-21 |
DE102011053521A1 (en) | 2012-03-15 |
FR2964567B1 (en) | 2013-03-15 |
KR101932766B1 (en) | 2018-12-26 |
CN102397184A (en) | 2012-04-04 |
US10172785B2 (en) | 2019-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10172785B2 (en) | Dendrobium chrysotoxum extract and its cosmetic use as an anti-aging agent | |
RU2545708C2 (en) | Moringa sp. whole seed extract and using it in cosmetic and/or dermatologic compositions | |
US8771758B2 (en) | Use of Tiliacora triandra in cosmetics and compositions thereof | |
US11213479B2 (en) | Cosmetic composition comprising a passionflower extract and edelweiss cells, and uses | |
KR101824770B1 (en) | Anti-wrinkle cosmetic composition comprising essentially Polygonum multiflorum adventitious extract | |
CA2799083C (en) | Use of tiliacora triandra in cosmetics and compositions thereof | |
JP5626650B2 (en) | Cosmetic composition containing orchid extract | |
US20190328650A1 (en) | Cosmetic use of the essential oil of laserpitium siler l. against the signs of aging of the skin and as a skin antioxidant | |
KR20160091300A (en) | Use of a brassocattleya marcella koss orchid extract as an active agent to prevent or delay the appearance of signs of cutaneous aging | |
KR20090127240A (en) | Method of anti-ageing cosmetic care by stimulation of survivin expression | |
KR100903654B1 (en) | Cosmetic compositions comprising Prunella Vulgaris extract and Adenosine | |
KR20130057091A (en) | Skin external composition containing extracts of chrysanthemum indicum var. albescens | |
KR100561036B1 (en) | Skin external preparation composition containing the extract of Seol and Kwonbaek as an active ingredient | |
KR101027113B1 (en) | Method for cosmetic composition containing pine endodermis extract from Pinus thunbergii Parl. | |
US20130028849A1 (en) | Agent For Stimulating The Expression of Loxl | |
KR102370802B1 (en) | External Composition for Skin Containing the Mixture of the Root Extract of Taraxacum officinale, Caffeine and Tocopherol | |
KR20050038381A (en) | A cosmetic composition containing extract of campsis grandiflora and/or torreya nucifera seed | |
KR20090089982A (en) | Cosmetic compositions containing extract of empetrum nigrum var. japonicum used for antiwrinkle | |
KR102533787B1 (en) | Antioxidant effect on flavonoids and polyphenols of Ceratopteris thalictroides extract, and cosmetic composition for preventing skin aging, or for preventing or improving skin wrinkles | |
KR20190107454A (en) | Composition Containing Euryale ferox Seed Extract for Anti-Aging of the Skin and Reinforcement of Skin Barrier Function | |
KR20230010994A (en) | Multifunctional cosmetic composition containing peat extracts and salts effective for skin wrinkle improvement, whitening, cell regeneration, and wound healing as an active ingredient | |
KR20110037463A (en) | Cosmetic composition for improving skin wrinkles containing astilbe chinensis extracts and adenosine | |
KR20150065028A (en) | A cosmetic composition for skin whitening comprising the extract of derris dalbergioides baker as active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: LVMH RECHERCHE, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LEPLANQUAIS, VIRGINIE;ANDRE, PATRICE;PECHER, VIRGINIE;REEL/FRAME:027137/0464 Effective date: 20111025 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |